sulpiride and Chronic Disease
sulpiride has been researched along with Chronic Disease in 33 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 9.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
"In lumbar cerebrospinal fluid (CSF) obtained from patients with chronic tension-type headache (CTH), the concentrations of beta-endorphin, met-enkephalin, dynorphin, cholecystokinin (CCK), calcitonin gene-related peptide (CGRP), and somatostatin were measured before and after 8 weeks of treatment with sulpiride or paroxetine." | 9.07 | Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. ( Bach, FW; Ekman, R; Langemark, M; Olesen, J; Rehfeld, JF; Schifter, S, 1994) |
" A serotonin re-uptake inhibitor, paroxetine (20-30 mg daily), and a dopamine antagonist, sulpiride (200-400 mg daily) were compared in a randomized, double-blind, response-conditional cross-over pilot study in 50 non-depressed patients with chronic tension-type headache." | 9.07 | Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. ( Langemark, M; Olesen, J, 1994) |
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 9.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
" Following this, two dosage regiments, a morning only dose, and the same daily total dose in two equal fractions at 8 a." | 6.65 | Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. ( Bond, HR; Curry, SH; Lewis, DM, 1983) |
"Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
"Sulpiride is a selective dopamine D2 antagonist." | 5.35 | Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. ( Chen, HJ; Chiu, NC; Ho, CS; Lue, HC; Shen, EY, 2009) |
"This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 5.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
" In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
"In lumbar cerebrospinal fluid (CSF) obtained from patients with chronic tension-type headache (CTH), the concentrations of beta-endorphin, met-enkephalin, dynorphin, cholecystokinin (CCK), calcitonin gene-related peptide (CGRP), and somatostatin were measured before and after 8 weeks of treatment with sulpiride or paroxetine." | 5.07 | Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. ( Bach, FW; Ekman, R; Langemark, M; Olesen, J; Rehfeld, JF; Schifter, S, 1994) |
" A serotonin re-uptake inhibitor, paroxetine (20-30 mg daily), and a dopamine antagonist, sulpiride (200-400 mg daily) were compared in a randomized, double-blind, response-conditional cross-over pilot study in 50 non-depressed patients with chronic tension-type headache." | 5.07 | Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial. ( Langemark, M; Olesen, J, 1994) |
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 5.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
" To enhance PRL release, we induced hyperprolactinemia by administering chronic injections of sulpiride (40 mg." | 3.71 | Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. ( Ahidouch, A; Authie, D; Beauvillain, JC; Carpentier, F; Cousse, H; Croix, D; Dewailly, E; Dupouy, JP; Fournier, S; Le Bourhis, X; Legrand, G; Prevarskaya, N; Raynaud, JP; Slomianny, C; Van Coppenolle, F, 2001) |
" The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction." | 2.68 | One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. ( Alberts, JL; Barnes, TR; Curson, DA; Pantelis, C; Speller, JC, 1997) |
"22 patients (8 manic-depressive psychoses and 14 schizophrenias) were given sultopride as the sole therapy, in a daily dose of 4 vials." | 2.65 | [Longterm psychosis and sultopride]. ( Morel, D, 1983) |
" Following this, two dosage regiments, a morning only dose, and the same daily total dose in two equal fractions at 8 a." | 2.65 | Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. ( Bond, HR; Curry, SH; Lewis, DM, 1983) |
"Treatment with sulpiride was associated with a significant rise in plasma prolactin level, but paradoxically these patients had significantly reduced extrapyramidal symptoms." | 2.65 | A clinical and pharmacodynamic evaluation of sulpiride. ( Bailey, J; Bishop, M; Coppen, A; Rao, VA, 1981) |
" Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
" In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or =1200 mg/day may be administered." | 2.41 | Amisulpride: a review of its use in the management of schizophrenia. ( Curran, MP; Perry, CM, 2001) |
"Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
"Sulpiride is a selective dopamine D2 antagonist." | 1.35 | Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. ( Chen, HJ; Chiu, NC; Ho, CS; Lue, HC; Shen, EY, 2009) |
Research
Studies (33)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (36.36) | 18.7374 |
1990's | 6 (18.18) | 18.2507 |
2000's | 14 (42.42) | 29.6817 |
2010's | 1 (3.03) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Espinosa-Juárez, JV | 1 |
Jaramillo-Morales, OA | 1 |
López-Muñoz, FJ | 1 |
Mendhekar, DN | 1 |
Terai, H | 1 |
Shimahara, M | 1 |
Ho, CS | 1 |
Chen, HJ | 1 |
Chiu, NC | 1 |
Shen, EY | 1 |
Lue, HC | 1 |
del Rosario, CN | 1 |
Pacchioni, AM | 1 |
Cancela, LM | 1 |
Sechter, D | 1 |
Peuskens, J | 1 |
Fleurot, O | 1 |
Rein, W | 3 |
Lecrubier, Y | 2 |
French, K | 1 |
Eastwood, D | 1 |
Kotler, M | 1 |
Strous, RD | 1 |
Reznik, I | 1 |
Shwartz, S | 1 |
Weizman, A | 1 |
Spivak, B | 1 |
Quintin, P | 1 |
Bouhassira, M | 1 |
Perrin, E | 1 |
Lancrenon, S | 1 |
Morel, D | 1 |
Lewis, DM | 1 |
Bond, HR | 1 |
Curry, SH | 1 |
Miyachi, Y | 1 |
Mizuchi, A | 1 |
Hamano, H | 1 |
Sarai, K | 1 |
Rao, VA | 1 |
Bailey, J | 1 |
Bishop, M | 1 |
Coppen, A | 1 |
Edwards, JG | 1 |
Alexander, JR | 1 |
Alexander, MS | 1 |
Gordon, A | 1 |
Zutchi, T | 1 |
Maier, W | 1 |
Benkert, O | 1 |
Bach, FW | 1 |
Langemark, M | 2 |
Ekman, R | 1 |
Rehfeld, JF | 1 |
Schifter, S | 1 |
Olesen, J | 2 |
Freeman, HL | 1 |
Speller, JC | 1 |
Barnes, TR | 1 |
Curson, DA | 1 |
Pantelis, C | 1 |
Alberts, JL | 1 |
Möller, HJ | 2 |
Coulouvrat, C | 1 |
Dondey-Nouvel, L | 2 |
Colonna, L | 1 |
Saleem, P | 1 |
Van Coppenolle, F | 1 |
Slomianny, C | 1 |
Carpentier, F | 1 |
Le Bourhis, X | 1 |
Ahidouch, A | 1 |
Croix, D | 1 |
Legrand, G | 1 |
Dewailly, E | 1 |
Fournier, S | 1 |
Cousse, H | 1 |
Authie, D | 1 |
Raynaud, JP | 1 |
Beauvillain, JC | 1 |
Dupouy, JP | 1 |
Prevarskaya, N | 1 |
Curran, MP | 1 |
Perry, CM | 1 |
Mielke, DH | 1 |
Gallant, DM | 1 |
Roniger, JJ | 1 |
Kessler, C | 1 |
Eckmann, F | 1 |
Lepola, U | 1 |
Koskinen, T | 1 |
Rimón, R | 1 |
Salo, H | 1 |
Gordin, A | 1 |
Zarebinski, JM | 1 |
Meltzer, HY | 1 |
Yamagami, S | 1 |
Kiriike, N | 1 |
Kawaguchi, K | 1 |
Masciocchi, A | 1 |
Reitano, S | 1 |
Vanini, M | 1 |
Cicchetti, V | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
4 reviews available for sulpiride and Chronic Disease
Article | Year |
---|---|
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double- | 1997 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
Amisulpride: a review of its use in the management of schizophrenia.
Topics: Acute Disease; Administration, Oral; Adsorption; Amisulpride; Antipsychotic Agents; Chronic Disease; | 2001 |
Trials
16 trials available for sulpiride and Chronic Disease
Article | Year |
---|---|
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease | 2002 |
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Anxiety; Basal Ganglia Diseases; Benzodiazepines; C | 2004 |
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
[Longterm psychosis and sultopride].
Topics: Adult; Amisulpride; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Ps | 1983 |
Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens.
Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mid | 1983 |
A clinical and pharmacodynamic evaluation of sulpiride.
Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Middle | 1981 |
Controlled trial of sulpiride in chronic schizophrenic patients.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Bli | 1980 |
Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.
Topics: Adult; Anxiety; Case-Control Studies; Chronic Disease; Cross-Over Studies; Depressive Disorder; Doub | 1994 |
Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache.
Topics: Adult; Aged; Basal Metabolism; Calcitonin Gene-Related Peptide; Cholecystokinin; Chronic Disease; Do | 1994 |
Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Musc | 1994 |
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Humans | 1997 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
[Clinical studies with sulpiride in schizophrenics hospitalized for many years].
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Schizophr | 1978 |
Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Meth | 1989 |
A single-blind study of clocapramine and sulpiride in hospitalized chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Dibenzazepines; Female; Humans; Male; Middle Aged; Psychiatric Status Rating | 1988 |
Other Studies
13 other studies available for sulpiride and Chronic Disease
Article | Year |
---|---|
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Hyperpigmentation with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Fluvox | 2009 |
Chronic tongue ulceration resolved by sulpiride: a report of two cases.
Topics: Aged, 80 and over; Candidiasis, Oral; Chronic Disease; Dopamine Antagonists; Female; Humans; Oral Ul | 2009 |
Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder.
Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Dopamine Antagonists; Dose-Response Relationsh | 2009 |
Influence of acute or repeated restraint stress on morphine-induced locomotion: involvement of dopamine, opioid and glutamate receptors.
Topics: Acute Disease; Animals; Benzazepines; Chronic Disease; Dizocilpine Maleate; Dopamine Antagonists; Do | 2002 |
Response of catatonic schizophrenia to amisulpride: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Humans; Male; Schizophrenia, Catatonic; S | 2003 |
Effects of chronic sultopride treatment on endocrine systems in psychotic women.
Topics: Adult; Amisulpride; Chronic Disease; Estradiol; Female; Follicle Stimulating Hormone; Growth Hormone | 1984 |
[Amisulpride--a neuroleptic agent for all phases of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Humans; Hyperkinesis; Hypertension; Risk Factors | 1999 |
Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.
Topics: Animals; Apoptosis; Chronic Disease; Dihydrotestosterone; Dopamine Antagonists; Gonadal Steroid Horm | 2001 |
Sulpiride: evaluation of antipsychotic activity in chronic schizophrenic patients.
Topics: Antipsychotic Agents; Chronic Disease; Humans; Schizophrenia; Sulpiride | 1977 |
Sulpiride in the treatment of chronic schizophrenia.
Topics: Chlorpromazine; Chronic Disease; Drug Therapy, Combination; Humans; Male; Schizophrenia; Sulpiride | 1989 |
Effect of neuroleptics on the schizophrenic syndrome.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clozapine; Female; Humans; Male; Schiz | 1987 |
[Preliminary results of a controlled trial with sulpiride versus chlorimipramine in chronic schizophrenic patients with marked ideo-emotional poverty (author's transl)].
Topics: Affect; Anxiety; Chronic Disease; Clomipramine; Depression; Dibenzazepines; Humans; Mental Processes | 1974 |